Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: A randomized study

Verhoeven, Marieke O.; Hemelaar, Majoie; Teerlink, Tom; Kenemans, P.; Mooren, M.J. van der

doi:10.1016/j.atherosclerosis.2006.09.018

Cited by 12 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Arginine concentrations are reported to be higher in in the follicular phase compared to the luteal phase 11 , although one study did not observe any changes in arginine concentrations during the menstrual cycle 12 . Lower ADMA concentrations have been reported in conditions associated with higher estrogen concentrations, as in pregnancy 22 , after ovarian hyperstimulation 23 and after hormone therapy in postmenopausal women 24 , which are observations in agreement with the results in the present study. We observed no differences in SDMA according to hormonal contraceptive use.…”

Section: Discussionsupporting

confidence: 93%

“…We observed no differences in Arg/ADMA ratio. The Arg/ADMA ratio was reported to be higher in OC-users compared to non-users in one study 11 , while no change was seen in postmenopausal women after hormone replacement 24 . Slightly higher Arg/ADMA ratios have been found in pregnant women in their second and third trimester, although this was not related to improved endothelial function 22 .…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Plasma Homoarginine Concentrations According to Use of Hormonal Contraception

Helm

Varsi

Fløtre

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Estrogen is a potent vasodilator through activation of endothelial nitric oxide synthase (eNOS). Arginine and its homologue homoarginine are substrates for NOS, while asymmetric dimethylarginine (ADMA) is a NOS inhibitor. Healthy, never-pregnant women aged 18 to 40 years (n = 158) were categorized according to use of hormonal contraception into non-users (n = 76), users of estrogen contraceptives (EC-users, n = 58) and users of progestins-only contraceptives (PC-users, n = 24). Plasma homoarginine, arginine, ADMA and SDMA concentrations were assayed using a LC-MS/MS method. Compared to non-users, EC users had higher plasma homoarginine (median (interquartile range) 1.63 (1.24, 2.04) vs. 2.39 (2.05, 2.85) µmol/L, p < 0.001), lower arginine (80.8 (72.4, 94.3) vs. 72.1 (62.9, 85.1) µmol/L, p = 0.008) and ADMA (0.52 (0.46, 0.59) vs. 0.48 (0.42, 0.54) µmol/L, p = 0.003) concentrations. The lowest median plasma homoarginine concentration (1.34 (0.92, 1.75) µmol) was seen in PC-users. No differences were seen in SDMA concentrations according to use of hormonal contraception. In healthy, never-pregnant women aged 18 to 40 years, use of estrogen containing contraception was associated with significantly higher plasma concentrations of homoarginine and lower plasma concentrations of arginine and ADMA as compared to non-users, while the lowest plasma homoarginine concentrations were seen in progestin-only users. Whether the observed changes in relation to use of hormonal contraception have an impact on cardiovascular status, should be evaluated in an intervention study.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 93%

Plasma Homoarginine Concentrations According to Use of Hormonal Contraception

Helm

Varsi

Fløtre

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…It is possible that renal and extrarenal DDAH activity decreases with age. This would explain the delayed increase in plasma ADMA in women because estrogen stimulates DDAH activity83 and oral 17-β estradiol replacement in postmenopausal women reduces plasma ADMA 84…”

Section: Substrate (L-arginine) Availability and Circulating Nos Inhimentioning

confidence: 99%

Sexual Dimorphism, the Aging Kidney, and Involvement of Nitric Oxide Deficiency

Baylis¹

2009

Seminars in Nephrology

View full text Add to dashboard Cite

Summary Females develop less age-dependent loss of renal function, in part because of cardiorenal protective effects of estrogens. The low androgen level in women also may be protective, although the animal and clinical data are controversial. Both estrogen and androgens act through multiple mechanisms, sometimes beneficial, sometimes damaging, which makes it difficult to predict the impact of hormone replacement therapy in an aging population. Nitric oxide (NO) deficiency contributes to age-dependent cardiovascular risk and kidney damage in animal models. The increased oxidative stress of aging impacts at multiple sites in the NO biosynthetic pathway to decrease NO production/action. Endothelial dysfunction develops with aging and is delayed in women, in association with a delayed increase in asymmetric dimethylarginine. Animal data suggest that the aging kidney develops NO deficiency because of changes in the neuronal NO synthase. Relative preservation of NO production in females contributes to the better cardiovascular and renal responses to aging.

show abstract

“…Oral contraceptives (OCs) are known to lower ADMA concentrations significantly in women with PCOS (9), and orally administered hormone replacement therapy (HRT) also has an effect on circulating ADMA levels (13)(14)(15). Our own studies and those of others have shown that during normal pregnancy, when there are high circulating estrogen levels, ADMA and SDMA concentrations are significantly decreased compared to the levels of non-pregnant women (10,16,17).…”

Section: Introductionmentioning

confidence: 99%

ADMA concentration changes across the menstrual cycle and during oral contraceptive use: the Cardiovascular Risk in Young Finns Study

Valtonen

Punnonen²,

Saarelainen³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate changes in the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) levels during different menstrual cycle phases in young adult women with or without oral contraceptive (OC) use. Design and methods: The subjects (nZ1079) originated from a large population-based, prospective cohort study conducted in Finland. Plasma ADMA, symmetric dimethylarginine (SDMA), L-arginine, C-reactive protein, creatinine, and brachial artery flow-mediated dilatation (FMD) were measured. The use of OCs and menstrual cycle phase were determined from a questionnaire. Results: In non-OC users, ADMA (PZ0.017), L-arginine (PZ0.002), and ADMA/SDMA ratio (P!0.001) were significantly lower in the luteal phase than in the follicular phase of the menstrual cycle. Non-OC users also had significantly higher ADMA and SDMA concentrations (P!0.001) and lower L-arginine concentrations (P!0.001) compared to OC users of estrogen-containing pills. Progestin-only contraceptive pills (POPs) did not lower the ADMA level, but maintained it at the same level as in non-OC users. In OC users, there were no significant differences found in ADMA, FMD, or FMD% across menstrual cycle, whereas brachial artery diameter was significantly more decreased in the luteal phase (PZ0.013) than in the follicular phase. Conclusion: We observed that the circulating ADMA concentration varies across the menstrual cycle in young women not using OCs, and women on OCs displayed significantly lower circulating ADMA concentrations than non-OC users, though this was not the case with POP contraception.

show abstract

Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: A randomized study

Cited by 12 publications

References 34 publications

Plasma Homoarginine Concentrations According to Use of Hormonal Contraception

Plasma Homoarginine Concentrations According to Use of Hormonal Contraception

Sexual Dimorphism, the Aging Kidney, and Involvement of Nitric Oxide Deficiency

ADMA concentration changes across the menstrual cycle and during oral contraceptive use: the Cardiovascular Risk in Young Finns Study

Contact Info

Product

Resources

About